Novo Nordisk vs. Pfizer: Evaluating Growth Versus Value in Pharma for 2027

As the global healthcare sector shifts toward specialized weight-loss treatments, everyday investors are examining the financial profiles of industry giants Novo Nordisk and Pfizer. Novo Nordisk has established a strong market footprint through its popular diabetes and weight-loss medications, reaching a revenue of roughly $49.3 billion and a net income of about $16.7 billion for the 12 months ended September 30, 2026. This performance reflects a robust net margin of roughly 34%, driven by surging global demand for its GLP-1 portfolio across roughly 170 countries.

Conversely, Pfizer operates as a broad-based biopharmaceutical enterprise managing a diverse mix of vaccines and medicines. For the 12 months ended September 27, 2026, Pfizer generated approximately $63.6 billion in revenue with a net income of roughly $4.0 billion, yielding a net margin of about 6.3%. The company maintains a solid free cash flow of around $9.1 billion for the fiscal year ended December 31, 2025, supporting its dividend payouts and ongoing reinvestment initiatives despite navigating a post-pandemic environment and government-mandated price negotiations.

Both companies encounter distinct operational hurdles heading toward 2027. Novo Nordisk faces mounting competition in the weight-loss sector from rivals like Eli Lilly, alongside manufacturing constraints that could restrict its capacity to fulfill global demand. Meanwhile, Pfizer must contend with significant pricing pressures from government bodies and private payers, as well as revenue erosion from generic and biosimilar product launches anticipated between 2026 and 2030. Valuation metrics indicate that Pfizer trades at a more affordable level through lower Forward P/E and price-to-sales ratios, whereas Novo Nordisk commands a valuation premium for its accelerated growth.

What to watch next: Monitor upcoming quarterly earnings reports for shifts in profit margins and global manufacturing updates for key GLP-1 and pharmaceutical portfolios.